Eisai gets epigenetic enzyme development rights from Epizyme; Epizyme takes back most rights
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
- Includes Contract
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.